



The association of the Stanford Expectations of Treatment Scale (SETS) with pain and opioid dose expectations during a tapering program

Eric Cramer MS & Beth Darnall PhD
Stanford University
April 24, 2021



Introduction

Many calls to reduce opioid prescribing, but not enough research supporting methods/how.

“No good data to guide opioid tapering”
(Eccleston et al, 2017)

“Guidelines are too aggressive”
(Berna et al, 2015)



What has prior work looked at?

Past opioid taper studies point to patient willingness to predict taper success.

Patient-Centered Prescription Opioid Tapering in Community Outpatients With Chronic Pain (Darnall et al 2018 JAMA Internal Medicine)

Broader healthcare research indicates patient expectations for treatment play a critical role in treatment outcome.

Implications of Placebo and Nocebo Effects for Clinical Practice: Expert Consensus (Evers et al 2018 Psychotherapy & Psychosomatics)



What do we still need to do?

Examine the role of patient expectations in the opioid taper process.

What kinds of expectancies are important to measure?



Our objective

Examine at baseline patient expectations (positive/negative) for an opioid tapering study with their expectations for pain and opioid dose changes to occur during their taper.



The study: **EMPOWER**

EFFECTIVE MANAGEMENT OF PAIN AND OPIOID-FREE WAYS TO ENHANCE RELIEF

Study overview

Study Description


- Patient-centered opioid tapering program
 - Collaborative
 - Personalized
 - Voluntary
- Randomized controlled trial
 - Cognitive Behavioral Therapy (pain-CBT)
 - Chronic Pain Self-Management Program (CPSMP)
 - Focus on taper plan
- Pragmatic study, outpatient setting

Study Aims

- Help patients achieve their lowest comfortable opioid dose without increased pain at 12 months
- Comparative effectiveness of two behavioral treatment groups



Study design



Inclusion Criteria

- 18-85 years old
- Chronic pain (not related to cancer) for at least 6 months
- Taking ≥ 10 MEDD of prescription opioids daily for at least 3 months
- No moderate or severe Opioid Use Disorder (OUD)
- Not pregnant
- English fluent
- Appropriate for group classes
- Interested in tapering

Demographics

- n = 210 patients
- 55.8% Male
- Race & ethnicity breakdown:
 - 85.0% Caucasian
 - 3.0% more than one race
 - 6.5% Hispanic
- Income breakdown:
 - 44.7% less than \$50,000/yr household income
 - 7.5% greater than \$150,000/yr household income
- Four state study: CA, AZ, CO, UT



Variables and Measures

- Stanford Expectations of Treatment Scale
 - Positive and negative expectations for tapering experience
- Pain Expectations
- Opioid Dose Reduction Expectations

Detailed in *Comparative Effectiveness of Cognitive Behavioral Therapy for Chronic Pain and Chronic Pain Self-Management within the Context of Voluntary Patient-Centered Prescription Opioid Tapering: The EMPOWER Study Protocol* (Darnall et al 2020)

doi.org/10.1093/pm/pnz285

ClinicalTrials.gov Identifier: NCT03445988



Variables: Stanford Expectations of Treatment Scale or SETS

- Example items:
 - “Reducing my opioids will be helpful for me.”
 - “I have fears about reducing my opioids.”
 - “I have confidence in working with my doctor to reduce my opioids.”
 - “I am nervous about possible negative effects of reducing my opioids.”
- Each is scored on a Numeric Rating Scale from 0 - 10

Validated in *Development of the Stanford Expectations of Treatment Scale (SETS): A tool for measuring patient outcome expectancy in clinical trials* (Younger et al 2012)

doi.org/10.1177/1740774512465064



Variables: Pain Expectations

- “Over the course of the study, I expect my pain to:”
 - “Improve substantially”
 - “Improve somewhat”
 - “Remain about the same”
 - “Worsen somewhat”
 - “Worsen substantially”

Variables: Opioid Dose Expectations

- “Over the course of the study, I expect my pain to:”
 - “How much do you expect your opioid dose will DECREASE (%) over the duration of the 12 month study period?”



Methods


Poly-ordinal logistic regression to examine the relationship between SETS positive and negative with pain expectations.

Linear Modeling to investigate the relationship between the SETS positive and negative scores with opioid taper expectations.




Results

Distribution of SETS positive expectations for tapering experience




Distribution of SETS negative expectations for tapering experience




Poly-Ordinal Regression of Pain Expectation

Predictor	Odds Ratio	Lower 95 CI	Upper 95 CI	McFadden's pseudo-R ²	p-value
SETS Positive	0.784	0.711	0.864	0.039	p < 0.001
SETS Negative	1.215	1.108	1.335	0.027	p < 0.001

SETS positive subscale score with expected change in pain level




SETS negative subscale score with expected change in pain level




Linear Regression of Opioid Reduction Expectation

Predictor	Coefficient	Lower 95 CI	Upper 95 CI	R ²	p-value
SETS Positive	4.010	2.577	5.444	0.123	p < 0.001
SETS Negative	-1.257	-2.771	0.257	0.008	0.103

SETS positive subscale score with expected opioid dose reduction



SETS negative subscale score with expected opioid dose reduction



Conclusions

- Prior to the start of a taper, SETS positive expectations for the tapering experience is associated with:
 - Lower expected pain intensity
 - Larger expected opioid dose reductions
- The inverse is true for the SETS negative expectations for taper experience (for pain expectations only).

Limitations and future work

- Limitations:
 - Selection bias in the population examined
 - Small sample size
 - Did not control for treatment site
- Future directions:
 - Investigate influencing expectations to improve outcome in future studies

Takeaways

- Important for physician/clinician to help patient with **setting expectations** before starting an opioid tapering program.
- **Early intervention** to change preconceived notions about treatment can increase benefits and minimize adverse effects.
- **Moving forward**: we may be able to help set positive expectations by focusing on collaborative decision making and close communication.



Acknowledgements

Luzmercy Perez
Lanja Sinjary
Ming-Chih Kao, PhD, MD
Jesmin Ram
Aram Mardian, MD
Ming-Chih Kao, PhD, MD
Sean Mackey, MD, PhD
Heather Okvat, PhD
Jeremiah West, MD
Garrick Olsen
Kate Lorig, PhD
Wendy Schadle
Anu Roy, MA
Lu Tian, PhD
Joel Porter, MD
Penney Cowan
Mark McGovern, PhD
Ting Pun, PhD

Matt Cheung, PharmD
Nathan Moore, MD
Luana Colloca, MD, PhD
Maisa Ziadni, PhD
Pamela Flood, MD
Heather King, PhD
Sophia You, PhD
Corinne Jung, PhD
Richard Stieg, MD, MPH
Korina DeBruyne, MD
Phil Lavori, PhD
Angie Chen, MD
Jim Weil
Penney Cowan
Patient Advisors
Jessica Root
Joshua Goff
Kelly Adams

